Viatris VTRS
NASDAQ VTRS
$16.50 -0.11 (-0.66%)
As of: Sep 9, 2026 · 3:59 PM EDT

Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026)

Viatris (VTRS) posted Total Non-Current Liabilities of $18.8 billion for Q2 2026, down 6.64% on a QoQ basis from $20.1 billion in Q1 2026, and down 10.69% year-over-year from $21.0 billion in Q2 2025.

Analysis

Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends

Viatris has reported Total Non-Current Liabilities for 8 years, with the latest figure at $18.8 billion in Q2 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 10.69% year-over-year to $18.8 billion in Q2 2026; TTM through Jun 2026 was $18.8 billion, a 10.69% decrease from a year earlier, with the FY2025 full-year figure at $20.5 billion, down 2.19% from the prior year.
  • Total Non-Current Liabilities was $18.8 billion for Q2 2026 at Viatris, down from $20.1 billion in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $31.1 billion in Q1 2022, with the low at $18.8 billion in Q2 2026.
  • Average Total Non-Current Liabilities over 5 years is $24.2 billion, with a median of $24.8 billion recorded in 2024.
  • The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities slipped 18.58% in 2024, then fell 2.19% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $27.2 billion in 2022, then fell by 5.49% to $25.7 billion in 2023, then retreated by 18.58% to $20.9 billion in 2024, then decreased by 2.19% to $20.5 billion in 2025, then slipped by 8.33% to $18.8 billion in 2026.
  • The last three Total Non-Current Liabilities figures came in at $18.8 billion (Q2 2026), $20.1 billion (Q1 2026), and $20.5 billion (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Teva Pharmaceutical Industries 42.84 Bn 39.19 Bn 2.15 Bn 16.45 Bn
2 Viatris 19.13 Bn 18.24 Bn 1.46 Bn 18.76 Bn
3 Dr Reddys Laboratories 9.91 Bn 9.74 Bn 396.53 Mn 1.29 Mn
4 Amneal Pharmaceuticals 5.51 Bn 5.38 Bn 334.51 Mn 2.78 Bn
5 Bausch Health Companies 2.30 Bn 464.50 Mn 2.10 Bn 24.86 Bn
6 Alvotech 1.50 Bn 1.36 Bn 2.56 Mn 1.45 Bn
7 Ani Pharmaceuticals 1.49 Bn 1.13 Bn 165.89 Mn 881.37 Mn
8 Amphastar Pharmaceuticals 1.00 Bn 714.13 Mn 93.47 Mn 946.17 Mn
9 Fennec Pharmaceuticals 402.10 Mn 360.85 Mn 17.15 Mn 20.92 Mn
10 RedHill Biopharma 178.35 Mn 178.35 Mn - 1.86 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 18.76 Bn
Mar 31, 2026 20.09 Bn
Dec 31, 2025 20.47 Bn
Sep 30, 2025 20.88 Bn
Jun 30, 2025 21.01 Bn
Mar 31, 2025 20.98 Bn
Dec 31, 2024 20.93 Bn
Sep 30, 2024 23.09 Bn
Jun 30, 2024 24.01 Bn
Mar 31, 2024 25.50 Bn
Dec 31, 2023 25.70 Bn
Sep 30, 2023 26.23 Bn
Jun 30, 2023 26.18 Bn
Mar 31, 2023 26.64 Bn
Dec 31, 2022 27.19 Bn
Sep 30, 2022 27.74 Bn
Jun 30, 2022 29.51 Bn
Mar 31, 2022 31.13 Bn
Sep 30, 2021 32.88 Bn
Jun 30, 2021 34.54 Bn